Non-Hodgkin's lymphomas: Current classification and management

Ca-A Cancer Journal for Clinicians

Volumn 47, Issue 6, 1997, Pages 351-372

  Skarin, Arthur T ^a,b   Dorfman, David M ^b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; HUMAN; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR CLASSIFICATION;

EID: 0030819284     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.47.6.351     Document Type: Review

References (58)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Devesa SS, Fears T: Non-Hodgkin's lyniphoma time trends: United Slates and international data. Cancer Res 1992;52(Suppl):5432S-5440S.
3. Aisenberg AC: Coherent view of non-Hodgkin's lymphoma. J Clin Oncol 1995;13:2656-2675.
4. Shipp MA, Mauch PM, Harris NL: Non-Hodgkin's lymphomas. in DeVita VT Jr, Hellman S. Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. ed 5. Philadelphia. Lippincott-Raven, 1997, pp 2165-2219.
5. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-2135.
6. Skarin AT: Non-Hodgkin's lymphoma. Adv Intern Med 1989;34:209-242.
7. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
8. Dehner LP: Here we go again: A new classifica- tion of malignant lymphomas: A viewpoint from the trenches. Am J Clin Pathol 1995;103:539-540.
9. Pittaluga S, Bijnens L, Teodorovic I, et al: Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: A comparison with the Working Formulation. Blood 1996;87:4358-4367.
10. Grogan TM, Miller TP, Dahlberg S, et al: REAL classification of lymphoma allows improved delineation of histologic risk groups: A Southwest Oncology Group (SWOG) study. Proceedings of the American Society of Clinical Oncology 1996;15:425. Abstract.
11. Rozman C, Montserrat E: Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-1057.
12. Wagner SD, Martinelli V, Luzzatto L.: Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia. prolymphocylic leukemia. Waldenström's macroglobulinemia. and myeloma. Blood 1994;83:3647-3653.
13. Offit K, Parsa NZ, Filippa D, et al: t(9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation. Blood 1992;80:2594-2599.
14. Weisenburger DD, Armitage JO: Mantle cell lymphoma - an entity comes of age. Blood 1996;87:4483-4494.
15. Offit K, Lo Coco F, Louie DC, et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 1994;331:74-80.
16. Sandlund JT, Downing JR, Crist WM: Non-Hodgkin's lymphoma in children. N Engl J Med 1996;334:1238-1248.
17. Yano T, van Krieken JHJM, Magrath IT, et al: Histogenetic correlations between subcategories of small noncleavcd cell lymphomas. Blood 1992;79:1282-1290.
18. Armitage JO, Greer JP, Levine AM, et al: Peripheral T-cell lymphoma. Cancer 1989;63:158-163.
19. Pinkus GS, O'Hara CJ, Said JW: Peripheral/post-thymic T-cell lymphomas: A spectrum of disease: Clinical, pathologic, and immunologic features of 78 cases. Cancer 1990;65:971-998.
20. Kadin ME: Primary ki-1-positive anaplastic large-cell lymphoma - A distinct clinicopathologic entity. Ann Oncol 1994;5(Suppl 1):25-30.
21. Berliner N, Ault KA, Martin P, et al: Detection of clonal excess in lymphoproliferative disease by kappa/lambda analysis: Correlation with immunoglobulin gene DNA rearrangement. Blood 1986;67:80-85.
22. Fisher DE, Jacobson JO, Ault KA, et al: Diffuse large cell lymphoma with discordant bone marrow histology: Clinical features and biological implications. Cancer 1989;64:1879-1887.
23. Kilo MN, Dorfman DM: The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma. Am J Clin Pathol 1996;105:451-457.
24. Kaplan WD, Jochelson MS, Herman TS, et al: Gallium-67 imaging: A predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol 1990;8:1966-1970.
25. Shipp MA: Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has "high-risk" disease? Blood 1994;83:1165-1173.
26. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
27. Hermans JvGK, Krol AD, van Groningen K, et al: International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995;86:1460-1463.
28. Janicek M, Kaplan W, Neuberg D, et al: Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997;15:1631-1637. Abstract.
29. Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, et al: Clinical stage I non-Hodgkin's lymphoma: Long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 1994;69:1088-1093.
30. Mac Manus MP, Hoppe RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996;14:1282-1290.
31. Rosenberg SA: The low-grade non-Hodgkin's lymphomas: Challenges and opportunities. J Clin Oncol 1985;3:299-310.
32. Brice P, Solal-Celigny P, Lepage E, et al: A randomized study in low tumor burden follicular lymphoma between no treatment, prednimustine and interferon. Proceedings of the American Society of Clinical Oncology 1995;14:394. Abstract.
33. Freedman AS, Gribben JG, Neuberg D, et al: High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996;88:2780-2786.
34. Grossbard ML, Fidias P: Prospects for immunotoxin therapy of non-Hodgkin's lymphoma. Clin Immunol Immunopathol 1995;76:107-114.
35. Tallman MS, Hakimian D: Purine nucleoside analogs: Emerging roles in indolent lymphprolifer- ative disorders. Blood 1995;86:2463-2474.
36. Solal-Celigny P, Brice P, Brousse N, et al: Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996;14:514-519.
37. Connors JM, Klimo P, Fairey RN, et al: Brief chemotherapy and involved field radiation therapy for limited-stage histologically aggressive lymphoma. Ann Intern Med 1987;107:25-30.
38. Miller TP, Dahlberg S, Cassady JR, et al: Three cycles of CHOP (3) plus radiotherapy (RT) is superior to eight cycles of CHOP (8) alone for localized intermediate and high grade non-Hodgkin's lymphoma (NHL): A Southwest Oncology Croup Study. Proceedings of the American Society of Clinical Oncology 1996;15:411. Abstract.
39. Glick JH, Kim K, Earle J, et al: An ECOG randomized phase III trial of CHOP vs. CHOP + radiotherapy (XRT) for intermediate grade early stage non-Hodgkin's lymphoma (NHL). Proceedings of the American Society of Clinical Oncology 1996;14:391. Abstract.
40. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.
41. Shipp MA, Neuberg D, Janicek M, et al: High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study. J Clin Oncol 1995;13:2916-2923.
42. Haioun C, Lepage E, Gisselbrecht C, et al: Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1994;12:2543-2551.
43. Haioun C, Lepage E, Gisselbrecht C, et al: Autologous bone marrow transplantation (ABMT) versus sequential chemotherapy for aggressive non Hodgkin's lymphoma (NHL) in first complete remission (CR): A study of 542 patients (LNH87-2 Protocol). Blood 1995;86:457. Abstract.
44. Velasquez WS, Cabanillas F, Salvador P, et al: Effective salvage therapy for lymphoma with cisplatin in combination with high dose Ara-C and dexamethasone (DHAP). Blood 1988;71:117-122.
45. Wilson WH, Bryant G, Bates S, et al: EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993;11:1573-1582.
46. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545.
47. Magrath I, Adde M, Shad A, et al: Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996;14:925-934.
48. Soussain C, Patte C, Ostronoff M, et al: Small noncleaved cell lymphoma and leukemia in adults: A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 1995;85:664-674.
49. Coleman CN, Picozzi VJ Jr, Cox RS, et al: Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 1986;4:1628-1637.
50. Baro J, Richard C, Sierra J, et al: Autologous bone marrow transplantation in 22 adult patients with lymphoblastic lymphoma responsive to conventional dose chemotherapy. Bone Marrow Transplant 1992;10:33-38.
51. The International Non-Hodgkin's Lymphoma Classification Project: Application of the International Lymphoma Study Group (ILSG) classification of non-Hodgkin's lymphoma (NHL): Clinical characteristics and outcome of 1400 patients from 8 countries. Ann Oncol 1996;7(Suppl 3):2. Abstract.
52. Rogers J, Jackson J, Rosenberg J, et al: Clearance of BCL-2 (t14:18) from peripheral blood (PB) and bone marrow in patients (PTS) with relapsed low-grade or follicular (IWF:A-D) lym- phoma (NHL) following single-agent therapy with the chimeric anti-CD20 antibody (MAB) IDEC-C2B8. Ann Oncol 1996;7(Suppl 3):34.
53. Kaminski MS, Zasadny KR, Francis IR, et al: Iodine-131-Anti-Bl radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974-1981.
54. Schultze J, Cardoso A, Boussiotis V, et al: Generation of anli-follicular lymphoma specific T-cell mediated immunity. Ann Oncol 1996;7(Suppl 3):19. Abstract.
55. Webb A, Cunningham D, Cotter F, et al: Phase I BCL-2 antisense trial: Preliminary results. Ann Oncol 1996;7(Suppl 3):32. Abstract.
56. Alcorn MJ, Holyoake TL, Richmond L, et al: CD34-positive cells isolated from cryopreserved peripheral-hlood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity. J Clin Oncol 1996;14:1839-1847.
57. Shipp MA: Can we improve upon the International index? Ann Oncol 1996;7(Suppl 3):11. Abstract.
58. Skarin AT, Dorfman DM: Hodgkin's disease and non-Hodgkin's lymphomas, in Skarin AT: Atlas of Diagnostic Oncology, ed 2. London. Mosby-Wolfe, 1996. pp 465-525.